When did Jazz Pharmaceuticals report Q4 2024 earnings?

Jazz Pharmaceuticals (JAZZ) reported Q4 2024 earnings on February 25, 2025 after market close.

What were Jazz Pharmaceuticals's Q4 2024 revenue and EPS?

Jazz Pharmaceuticals reported revenue of $1.1B and eps of $6.60 for Q4 2024.

Did Jazz Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $985.0M by $103.2M. EPS beat the consensus estimate of $5.83 by $0.77.

Where can I find Jazz Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001232524-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.

Jazz Pharmaceuticals JAZZ Q4 2024 Annual earnings

Reported February 25, 2025 · After market close

Revenue$1.1BBeat by $103.2M

EPS$6.60Beat by $0.77

Revenue estimate$985.0M

EPS estimate$5.83

Next report

Aug 3, 2026 (In 4 days)

Revenue estimate$1.1B

EPS estimate$6.18

Financials

Q4 2024

Income statement

See full

Revenue$1.1B+7.5%

Operating income$190.8M+55.7%

Net income$191.1M+103%

EPS (diluted)$3.02+111%

Balance sheet

See full

Cash & equivalents$2.4B+60.2%

Total debt$6.2B+6.4%

Total equity$4.1B+9.5%

Total assets$12.0B+5.4%

Cash flow

See full

Operating cash flow$398.6M+138%

CapEx$13.3M+31.5%

Free cash flow$385.3M+145%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$7.44B-3.3%

Enterprise value$11.2B-6.6%

P/E13.3×-5.3×

P/S1.8×-0.2×

Profitability

See full

Operating margin17.6%+2.5pp

Net margin13.8%+2.9pp

FCF margin33.4%+5.5pp

Returns & leverage

See full

Return on equity14.3%+2.1pp

Debt / equity1.5×0.0×

Current ratio4.5×+2.2×

Segments

By product

See full

Xywav$401.0M+19.0%

Epidiolex/Epidyolex$275.0M+14.3%

Rylaze/Enrylaze$101.5M—

Zepzelca$78.3M+5.8%

Defitelio/defibrotide$57.7M+12.9%

By geography

See full

Europe$81.9M+9.1%

All other$32.7M+24.1%

Versus estimates

Revenue

Q1 2026$1.1BBeat by $90.2M Q4 2025$1.2BBeat by $32.7M Q3 2025$1.1BBeat by $15.0M Q2 2025$1.0BMiss by $1.5M Q1 2025$897.8MMiss by $167.0M

Q4 2024$1.1BBeat by $103.2M

Diluted EPS

Q1 2026$6.34Beat by $1.67 Q4 2025$6.64Beat by $0.12 Q3 2025$8.13Beat by $2.18 Q2 2025-$8.25Miss by $2.13 Q1 2025$1.68Miss by $2.83

Q4 2024$6.60Beat by $0.77

Ask the moment Jazz Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Jazz Pharmaceuticals report Q4 2024 earnings?: Jazz Pharmaceuticals (JAZZ) reported Q4 2024 earnings on February 25, 2025 after market close.
What were Jazz Pharmaceuticals's Q4 2024 revenue and EPS?: Jazz Pharmaceuticals reported revenue of $1.1B and eps of $6.60 for Q4 2024.
Did Jazz Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $985.0M by $103.2M. EPS beat the consensus estimate of $5.83 by $0.77.
Where can I find Jazz Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001232524-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.